Search

Your search keyword '"Zsofia Sztupinszki"' showing total 90 results

Search Constraints

Start Over You searched for: Author "Zsofia Sztupinszki" Remove constraint Author: "Zsofia Sztupinszki"
90 results on '"Zsofia Sztupinszki"'

Search Results

1. Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression

2. Are tumor-associated carbohydrates the missing link between the gut microbiome and response to immune checkpoint inhibitor treatment in cancer?

3. Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting

4. Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma

5. A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus

6. Author Correction: Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting

7. CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer

8. Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy

9. PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

10. Author Correction: A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus

11. A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients

12. A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures

15. Data from Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post–PD-1 Immunotherapy

16. Supplementary Figure from Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post–PD-1 Immunotherapy

17. Supplementary Figures and Tables from A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency

18. Table S4 from A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency

19. Data from A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency

21. Data from Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer

22. Supplementary Data from Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer

24. Data from Comparative Assessment of Diagnostic Homologous Recombination Deficiency–Associated Mutational Signatures in Ovarian Cancer

26. Supplementary Data from Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations

27. Data from Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer

29. Data from Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations

30. Comparative Assessment of Diagnostic Homologous Recombination Deficiency–Associated Mutational Signatures in Ovarian Cancer

31. Diagnostic tool to identify and treat DNA repair deficient gastroesophageal adenocarcinomas

32. A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures

33. Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy

34. Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations

35. Characterization of unique PMEPA1 gene splice variants (isoforms d and e) from RNA Seq profiling provides novel insights into prognostic evaluation of prostate cancer

36. RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer

37. RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics

38. RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer

39. PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

40. Circulating protein biomarkers for use in pancreatic ductal adenocarcinoma identification

41. Transcriptomic signatures of tumors undergoing T cell attack

42. Increased frequency of CHD1 deletions in prostate cancers of African American men is associated with distinct homologous recombination deficiency associated DNA aberration profiles

43. Strand Orientation Bias Detector to determine the probability of FFPE sequencing artifacts

44. A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency

45. Genetic Determinants of Somatic Selection of Mutational Processes in 3,566 Human Cancers

46. Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer

47. Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage

48. Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer

49. E3 ligase RFWD3 is a novel modulator of stalled fork stability in BRCA2-deficient cells

50. Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors

Catalog

Books, media, physical & digital resources